Eris Lifesciences share price
You have to be logged in to add this to Watchlist.- ₹1,757.95(-0.92%)July 18, 2025 15:29:00 PM IST
- NSE
- BSE
- Vol : 81.80K (NSE + BSE)Last 20 day avg : 201.95 K
Eris Lifesciences is trading -0.92% lower at Rs 1,757.95 as compared to its last closing price. Eris Lifesciences has been trading in the price range of 1,797.65 & 1,715.05. Eris Lifesciences has given 29.31% in this year & 1.86% in the last 5 days. Eris Lifesciences has TTM P/E ratio 54.83 as compared to the sector P/E of 25.87.There are 9 analysts who have initiated coverage on Eris Lifesciences. There are - analysts who have given it a strong buy rating & - analysts have given it a buy rating. - analysts have given the stock a sell rating.The company posted a net profit of 93.45 Crores in its last quarter.Listed peers of Eris Lifesciences include Syngene International (-1.93%), J B Chemicals And Pharmaceutical (-1.03%), Eris Lifesciences (-0.92%).The Mutual Fund holding in Eris Lifesciences was at 16.59% in 31 Mar 2025. The MF holding has increased from the last quarter. The FII holding in Eris Lifesciences was at 8.43% in 31 Mar 2025. The FII holding has increased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
Updated on Jul 19, 2025, 06:24 PM UTC
- Dividend YieldLower than industry0.43Annual dividends as a percentage of the stock price.
- P/B8.14The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values66.11Price-to-earnings ratio based on trailing 12-month earnings
- BetaLow volatility0.56Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.87The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable- The company's revenue grew in March quarter by 28.02% from Rs 705.30 crore to Rs 550.93 crore, year-on-year
- The company has grown its March quarter profit by 31.69% from Rs 70.96 crore to Rs 93.45 crore, year-on-year
The debt to equity of the company is higher than the industry median- Company can comfortably pay off its interest obligations with its earnings
- R1
- 1,781.80
- R2
- 1,879.00
- R3
- 1,964.00
- S1
- 1,599.60
- S2
- 1,514.60
- S3
- 1,417.40
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Syngene International | Neutral | 656.40 | -1.93 | 26,448.94 | 54.31 | 5.44 | 0.20 | 8.65 |
| J B Chemicals And Pharmaceutical | Bullish | 1,647.00 | -1.03 | 25,801.36 | 39.45 | 7.43 | 0.75 | 0.19 |
| Eris Lifesciences | Bullish | 1,757.95 | -0.92 | 23,866.14 | 66.44 | 8.2 | 0.43 | 62.42 |
| Alembic Pharmaceuticals | Bullish | 1,029.80 | -0.42 | 20,205.93 | 34.73 | 3.81 | 1.09 | 0.90 |
| Jubilant Pharmova | Bullish | 1,234.90 | 2.87 | 19,645.08 | 35.82 | 3.04 | 0.42 | 38.19 |
- Pledged found - Promoter(s) have pledged 18.51% of shares.
- Pledging Flat - Promoter(s) pledging has not increased in last quarter.
- Promoter(s) holds a high stake in the company at 54.85%
- Promoter(s) have decreased the stake in the company in last 12 months
- FIIs are invested in this company
- FIIs holding has increased by 0.07 percentage points from previous quarter
- Mutual Funds holding has increased by 0.07 percentage points from previous quarter
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-05-19 | Audited Results |
| 2025-02-07 | Interim Dividend |
| 2025-02-04 | Quarterly Results |
| 2024-10-25 | Quarterly Results |
| 2024-08-02 | Quarterly Results |
- IndustryBiotechnology & Drugs
- ISININE406M01024
- BSE Code540596
- NSE CodeERIS
Eris Lifesciences is trading at 1757.95 as on Fri Jul 18 2025 09:59:00. This is -0.92% lower as compared to its previous closing price of 1774.30.
The market capitalization of Eris Lifesciences is 23866.14 Cr as on Fri Jul 18 2025 09:59:00.
The 52 wk high for Eris Lifesciences is 1909.55 whereas the 52 wk low is 988.95
Eris Lifesciences can be analyzed on the following key metrics -
- TTM P/E: 54.83
- Sector P/E: 25.87
- Dividend Yield: 0.41%
- D/E ratio: 0.87
Eris Lifesciences reported a net profit of 351.84 Cr in 2025.
The Mutual Fund Shareholding was 16.59% at the end of 31 Mar 2025.